Showing results (431-440 of 601) with videos related to
Sort By:
Pageof 61
Neurology(R) Neuroimmunology & Neuroinflammation|April 11, 2023
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With OcrelizumabSteffen Pfeuffer, Leoni Rolfes, Jens Ingwersen, et al.Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.Journal of Neuroinflammation|July 10, 2012
Effects of dimethyl fumarate on neuroprotection and immunomodulationPhilipp Albrecht, Imane Bouchachia, Norbert Goebels, et al.Frontiers in Neurology|November 8, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosisEnrique Alvarez, Lawrence Steinman, Edward J Fox, et al.Journal of the Peripheral Nervous System : JPNS|July 7, 2020
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic reviewRichard A Lewis, David R Cornblath, Hans-Peter Hartung, et al.Neurology(R) Neuroimmunology & Neuroinflammation|May 28, 2021
Association of Retinal Layer Thickness With Cognition in Patients With Multiple SclerosisSharon Jean Baetge, Michael Dietrich, Melanie Filser, et al.Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.Pageof 61